Peng He, Jing Sun, Jian Tan, Ya-Ning Shi, Chan-Juan Zhang, Neng Zhu, Qiong Yang, Li Qin
{"title":"From Physicochemical Constraints to Clinical Prospects of Celastrol: Challenges and Nano Delivery Strategies.","authors":"Peng He, Jing Sun, Jian Tan, Ya-Ning Shi, Chan-Juan Zhang, Neng Zhu, Qiong Yang, Li Qin","doi":"10.2147/IJN.S539586","DOIUrl":null,"url":null,"abstract":"<p><p>Celastrol (CeT) is the first pentacyclic triterpenoid compound isolated from the root bark of <i>Tripterygium wilfordii</i>. It has a broad spectrum of pharmacological activities, including anti-fibrosis, anti-tumor, anti-inflammation, immunomodulation, antioxidation, and neuroprotective effects. Despite the considerable therapeutic potential, the clinical application of CeT has been severely hindered by several inherent limitations, including poor aqueous solubility and permeability, low oral bioavailability, short plasma half-life, cytotoxicity, organ toxicity and so on. In recent years, the rapid development of nanotechnology has provided innovative strategies to address these challenges. The targeted drug delivery system based on nanomaterials can improve the administration defects of CeT and enhance its therapeutic efficacy. This review systematically summarizes the challenges faced by CeT in the drug delivery process, and discusses the latest progress of nanodelivery strategies in overcoming these challenges from both active and passive targeting aspects, including the application of nanosystems such as polymer micelles, liposomes, nanoparticles and nanogels, and other nanosystems, providing references for the further development and clinical application of CeT.</p>","PeriodicalId":14084,"journal":{"name":"International Journal of Nanomedicine","volume":"20 ","pages":"10907-10931"},"PeriodicalIF":6.5000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420926/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Nanomedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJN.S539586","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"NANOSCIENCE & NANOTECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Celastrol (CeT) is the first pentacyclic triterpenoid compound isolated from the root bark of Tripterygium wilfordii. It has a broad spectrum of pharmacological activities, including anti-fibrosis, anti-tumor, anti-inflammation, immunomodulation, antioxidation, and neuroprotective effects. Despite the considerable therapeutic potential, the clinical application of CeT has been severely hindered by several inherent limitations, including poor aqueous solubility and permeability, low oral bioavailability, short plasma half-life, cytotoxicity, organ toxicity and so on. In recent years, the rapid development of nanotechnology has provided innovative strategies to address these challenges. The targeted drug delivery system based on nanomaterials can improve the administration defects of CeT and enhance its therapeutic efficacy. This review systematically summarizes the challenges faced by CeT in the drug delivery process, and discusses the latest progress of nanodelivery strategies in overcoming these challenges from both active and passive targeting aspects, including the application of nanosystems such as polymer micelles, liposomes, nanoparticles and nanogels, and other nanosystems, providing references for the further development and clinical application of CeT.
期刊介绍:
The International Journal of Nanomedicine is a globally recognized journal that focuses on the applications of nanotechnology in the biomedical field. It is a peer-reviewed and open-access publication that covers diverse aspects of this rapidly evolving research area.
With its strong emphasis on the clinical potential of nanoparticles in disease diagnostics, prevention, and treatment, the journal aims to showcase cutting-edge research and development in the field.
Starting from now, the International Journal of Nanomedicine will not accept meta-analyses for publication.